RecruitingPhase 3NCT06685978
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
Studying Catastrophic antiphospholipid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Intervention
- Xiang Ju Ru Pi Ning capsule Placebo(drug)
- Enrollment
- 430 enrolled
- Eligibility
- 18-50 years · FEMALE
- Timeline
- 2024 – 2026
Study locations (27)
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, Beijing Municipality, China
- East Hospital of Beijing University of Chinese Medicine, Beijing, Beijing Municipality, China
- Guang 'anmen Hospital, Beijing, Beijing Municipality, China
- Chongqing Traditional Chinese Medicine Hospital, Chongqing, Chongqing Municipality, China
- Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China
- Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
- Guang 'anmen Hospital Baoding Hospital, Baoding, Hebei, China
- Cangzhou Hospital of Integrated Chinese and Western Medicine, Cangzhou, Hebei, China
- Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, Hebei, China
- Oilfields General Hospital in Daqing, Daqing, Heilongjiang, China
- Luoyang Third People's Hospital, Luoyang, Henan, China
- Zhengzhou People's Hospital, Zhengzhou, Henan, China
- Wuhan Third Hospital, Wuhan, Hubei, China
- The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
- The First Affiliated Hospital of Hunan College of Traditional Chinese Medicine (Hunan Provincial Direct Hospital of Traditional Chinese Medicine), Zhuzhou, Hunan, China
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06685978 on ClinicalTrials.govOther trials for Catastrophic antiphospholipid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07458984FMT Capsules for rCDIHelsinki University Central Hospital
- RECRUITINGPHASE1NCT07297199A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55Biogen
- RECRUITINGPHASE3NCT07165951Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNANCT07561333Comparing ACB+IPACK and ACB+BiFeS Block Combinations for Analgesia in Total Knee ArthroplastyHitit University
- RECRUITINGPHASE2, PHASE3NCT06841679Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaBeijing Biostar Pharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07044271A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsEli Lilly and Company
- RECRUITINGPHASE1NCT06943677A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant TumorsChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2NCT06822946Zhibitai Capsules for the Treatment of Primary HyperlipidemiaChengdu Diao Jiuhong Pharmaceutical Factory